Guildford, UK, and Burlington, Mass. – IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, and Somaxa Ltd., a company specializing in medical data solutions for healthcare and pharmaceutical clients, today announced a strategic OEM partnership.

With this agreement, Somaxa will deploy IDBS’ InforSense Suite as its underlying technology platform to deliver innovative data analysis and visualization solutions to the healthcare and pharmaceutical industries, the first of which, “The UK Diabetes Intelligence Portal” is in development. InforSense enables researchers to seamlessly connect complex clinical, genomic and image data via interactive web-based visualisations that accelerate biomarker discovery and translational research.

“This partnership is an exciting opportunity for us, giving Somaxa access to one of the world’s leading platforms for advanced clinical research and healthcare analytics,” said Chris Hodkinson, Director of Somaxa. He added, “The InforSense Suite allows us to rapidly develop healthcare data solutions and to focus on exploiting the vast amount of electronic healthcare data available to improve pharmaceutical R&D, patient care and patient safety.”

“We are extremely happy to be working with Somaxa, whose expertise in delivering high quality analytical solutions and in-depth knowledge of the pharmaceutical industry reflects IDBS’ ethos and values,” said Chris Molloy, VP Corporate Development at IDBS. “Adding Somaxa to our list of partners extends the reach and capabilities of our new healthcare business unit.”

About Somaxa Ltd

With over 30 years combined experience in pharmaceutical research and development, Somaxa works with medical data and technology partners to deliver solutions to business problems for healthcare and pharmaceutical research and development.

About the IDBS Healthcare Unit

The IDBS Healthcare Unit is dedicated to the advancement of personalized medicines and improved patient outcomes through the delivery of advanced translational medicine and biomarker research informatics that bridge the worlds of clinical, molecular and image data. Our sophisticated data management and analytics solutions underpin improved disease understanding, more effective diagnosis and treatment selection. By delivering the enterprise infrastructures and managed services required for translational and biomarker studies, IDBS is revolutionizing research environments to enhance innovation, accelerate research and improve data and research quality. By working with leading organizations from bench to bedside, IDBS is enabling collaboration across the health science ecosystem.

About IDBS

IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations’ valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.

IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China.